Mallinckrodt announces u.s. fda filing acceptance of biologics license application for regenerative skin tissue therapy

Mallinckrodt announces u.s. fda filing acceptance of biologics license application for stratagraft® regenerative skin tissue for treatment of adults with deep partial-thickness thermal burns.mallinckrodt plc - fda granted application priority review and assigned a prescription drug user fee act (pdufa) target date of february 2, 2021.
MNK Ratings Summary
MNK Quant Ranking